![]() ![]() July 2022: Positive Data from Single-Center Named Patient Program as Maintenance TherapyĪugust 2022: Commencement of Phase 2 StudyĪpril 2022: Positive Data from Phase 1 Study in Stage 4 Metastatic TNBC ![]() March 2022: Publication of Positive Data from EAP Program ![]() March 2022: IND Clearance for Phase 2 Clinical Study As we come to the new year and milestones ahead, I think it’s worth reviewing some of the key accomplishments made in 2022, highlighted below: I am incredibly proud of our team and pleased with the advancements we’ve made. In 2022, our team successfully executed across our clinical development programs, including the initiation of clinical studies and commenced patient enrollment, as well as noteworthy progress on the corporate front. Over the course of the past year, the AIM management team and Board have worked dedicatedly to position the Company for continued success. The full text of the letter is as follows: (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today issued a letter to stockholders highlighting key accomplishments in 2022 and outlining corporate objectives for 2023. OCALA, Fla., Ma(GLOBE NEWSWIRE) - AIM ImmunoTech Inc. Poised to achieve multiple clinical and regulatory value-driving milestones in 2023 ↑ Crystal Research Associates (November 27, 2016), Hemispherx Biopharma, Inc.Year marked by noteworthy operational execution and clinical development progress across pipelineĬompany reiterates commitment to continued communication and activity with the investment and scientific communities.↑ Hasse, Javier (December 30, 2016), "Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It", Benzinga, Detroit Michigan."Hemispherx gets IP rights from the CEO it fired". "Philadelphia biotech firm fires longtime chairman & CEO". Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Reflecting Ampligen's® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS". ↑ Hemispherx Biopharma Inc (August 23, 2019).2016, Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear.2016, Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement (see also NIH Post-Infectious ME/CFS Study).2016, Executive Informational Overview by Crystal Research Associates.2016, Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It.2014, Investor's post about HEB's rocky history.2016, Small Cap Nation - ME/CFS (Updated) ( Thomas Equels).Main article: Marketing History of Ampligen Online presence Chief Scientific & Medical Officerīoard of directors Chief Operating Officer, Secretary, General Counsel, Executive Director for Governmental Relations Robert Dickey IV, CPA - Chief Financial Officer, Executive Vice Chairman.As part of the settlement, the intellectual property rights, including the patent for Ampligen and Alferon, are irrevocably assigned to to AIM ImmunoTech. Carter and Hemispherx, now AIM ImmunoTech, regarding the wrongful termination claim. In June 2016, the law suit was resolved between Dr. was promoted in house as his replacement. William Carter, then Chairman and CEO, was terminated by the board of directors of Hermispherx Biopharma, now AIM ImmunoTech, who cited that part of the reason was a strong financial austerity plan. In Jan 2018, Thomas Equels, chief executive officer of AIM ImmunoTech, released a letter instructing every Hemispherx employee to watch the documentary Unrest and urged their affiliates and stockholders to do the same, in an effort to share information about ME/CFS, one of the primary disease targets for their drug Ampligen. Ampligen is available to a small number of patients under the expanded access program. ![]() Ampligen® and Alferon® LDO are not FDA-approved and are considered experimental. To date, only Alferon N Injection® has FDA approval. In addition to Ampligen® (rintatolimod), AIM ImmunoTech produces Alferon N Injection® and Alferon® LDO (Low Dose Oral). AIM ImmunoTech's corporate headquarters are in Ocala, Florida (formerly in Philadelphia, PA) and the main manufacturing and research facility is in New Brunswick, NJ. AIM ImmunoTech, formerly known as Hemispherx Biopharma, is a small American pharmaceutical company that produces the drug Ampligen (rintatolimod). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |